NEWS FROM OUR LAB
Our recent paper on ‘RetroBioCat as a computer-aided synthesis planning tool for biocatalytic reactions and cascades’ was highlighted on the cover of Nature Catalysis.
This amazing cover art was done by Verena Resch from @luminous_lab. She also designed this website!
Professor Nicholas Turner was interviewed on ‘In the Active Site’ podcast
As part of Biotrans 2021, the scientists who are invited to give a lecture are interviewed. You can access the podcasts here http://biotrans2021.uni-graz.at/podcast.html
PhD student James Marshall presented his work at the NextGenBiocat conference
James recently published his work on screening of metagenomic IREDs in Nature Chemistry. You can read the paper here https://www.nature.com/articles/s41557-020-00606-w
Lucian Pirvu joins our group as a Post-doctoral Research Assistant
Read more about him on our members page
PREVIOUS NEWS FROM OUR LAB
Professor Nicholas Turner has been elected a Fellow of the Royal Society (FRS)
Fellows are elected based on excellence in science via a peer-review process and are thus some of the most eminent scientists from the UK.
CoeBio3 phase IV continues with the start of six new PhD students
CoeBio3 is the The Centre of Excellence for Biocatalysis, Biotransformations and Biocatalytic Manufacture. http://www.coebio3.manchester.ac.uk/
The centre is based in Manchester but supports PhD students at the University of York, The University of Liverpool and the University of Bristol. The program is supported by industrial affiliates from Merck, GSK, Novartis, AstraZeneca and more….
Professor Nicholas Turner will lead a “Prosperity Partnership” for
Developing new biocatalytic technologies for chemical manufacturing in the pharmaceutical industry
This AstraZeneca, Prozomix and The University of Manchester Prosperity Partnership will bring together their expertise to design and develop novel chemical manufacturing technologies, based upon engineered biocatalysts, with the aim of producing new therapeutic complex molecules.
Achieving this goal will require the generation of a new toolbox of biocatalysts that are able to catalyse particularly demanding transformations. This project has the potential to bring new medicines to patients, in addition to developing more sustainable manufacturing processes that reduce the impact on the environment.